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In this issue ofCancer Cell, Zheng et al. provide strong evidence that PLAGL2 serves as an oncogene in GBM.
They demonstrate that PLAGL2 inhibits differentiation and promotes a persistent, self-renewing state, at
least in part because of activation of Wnt signaling.Glioblastoma multiforme (GBM) is one of
the most aggressive and highly lethal
cancers. New avenues of treatment are
therefore desperately needed. However,
a great deal needs to be learned about
GBM biology prior to developing rational
therapies. In recent years, several dif-
ferent approaches have led to an explo-
sion in the knowledge of how GBM cells
proliferate, survive, and invade normal
tissue. On one front, there are almost daily
new and important discoveries of the
ways in which key oncogenic pathways
mediate their effects, how they interact,
and how they are activated. On another
front, advances in array and sequencing
technology, along with sophisticated bio-
informatics, are being used to identify
molecular alterations in GBM as well as
to group them into functionally meaningful
classifications. Additionally, the identifi-
cation of stem cell-like tumor initiating
cells within GBM has provided both an
advance in the conception of how tumors
may be initiated as well as new methods
to study GBM in vitro. These concepts
bring into play the rapidly accumulating
knowledge of the fundamental properties
of stem cells. Finally, the use of mouse
models and cells derived from these
models that carry oncogenic mutations
has facilitated the study of the process
of neoplastic transformation in a manner
that brings greater control than through
the use of human samples.
In the current issue of Cancer Cell,
Zheng et al. (2010) make use of all these
advances in an extensive and elegant
series of studies to set forth the argument
that PLAGL2, a putative transcription
factor, is a disease-causing or promoting
gene in GBM. PLAGL2 (Pleiomorphic
Adenoma Like 2) was identified becauseof its homology to PLAG1, which was
originally identified as being associated
with pleiomorphic adenomas (Kas et al.,
1997). Both PLAG1 and PLAGL2 have
been associated with the development
of malignancies, especially in acute mye-
logenous leukemia, in which they coop-
eratewith an aberrant fusion gene created
by an inversion of chromosome 16 to pro-
mote abnormal growth of hematopoetic
progenitors (Landrette et al., 2005). The
mechanisms by which PLAGL2 and
PLAG1 promote cancer are unknown.
Zheng et al. found amplification of
chromosome 20q11.21 in nearly 15% of
GBMs studied using the powerful data
set of The Cancer Genome Atlas project
(http://cancergenome.nih.gov). In order
to determine which of the nine genes
within this chromosomal region has the
oncogenic activity, Zheng et al. performed
overexpression of each of these genes in
astrocytes derived from Ink4a/Arf/
Pten/mice and found that PLAGL2 pro-
moted anchorage-independent growth.
Further studies were then conducted to
demonstrate the tumor-promoting actions
of PLAGL2, including anchorage indepen-
dent growth and invasiveness of P53/
astrocytes as well as the tumorigenesis
of transformed rat intestinal epithelial
cells. The latter finding, although not di-
rectly related to glioma formation, is con-
sistent with a tumor-promoting role for
PLAGL2 and also supports observations
of PLAGL2 amplification in colorectal
cancer.
In order to delineate cellular and poten-
tial molecular mechanisms of action, the
authors took advantage of detailed knowl-
edge of neural stem cell and cancer stem
cell biology and culture methods. Neural
stem cells can be cultured from the sub-Cancer Celventricular zone of mice with relative
ease in the presence of epidermal growth
factor and basic fibroblast growth factor.
Although the cell of origin of GBM is
debatable, because stem cell-like cells
cultured from GBM have many of the
characteristics of neural stem cells (e.g.,
Hemmati et al., 2003), neural stem cells
are now being used as a model to study
pathways and processes involved in the
development and propagation of brain
tumors. Zheng et al. cultured neural
stem cells from P53/ mice and exam-
ined the effects of overexpressing
PLAGL2. Upon withdrawal of mitogen
and adherence to substrate, neural stem
cell-containing cultures readily differen-
tiate into neurons and glia. Certain factors
can be used to enhance the differentiation
of neural stem cells along specific line-
ages. For example, BMP-2 can be used
to promote astrocytic differentiation
(Gross et al., 1996). PLAGL2 overexpres-
sion in neural stem cell-containing
cultures did not result in rapid prolifera-
tion, but instead inhibited differentiation,
even in the presence of BMP-2. These
findings suggest that one mechanism by
which PLAGL2 can promote GBM forma-
tion or growth is by allowing GBM cells to
remain in a self-renewing state, through
the prevention of differentiation. Similar
results were obtained with cultures ob-
tained from primary GBMs through the
same methods as for normal neural stem
cells. These cultures, although still subject
to in vitro artifacts, represent an advance
in the study of GBM compared to either
primary patient-derived cells grown in
serum or ‘‘standard’’ highly passaged
cell lines. They retain much of the cellular
heterogeneity of the GBM from which
they arise and form invasive tumors afterl 17, May 18, 2010 ª2010 Elsevier Inc. 417
Cancer Cell
Previewsxenotransplantation into immunodeficient
animals (Galli et al., 2004). Consistent
with a tumor-promoting role, PLAGL2-
transformed GBM cultures more readily
formed tumors after xenotransplantation.
In order to elucidate the potential
mechanisms of action of PLAGL2, Zheng
et al. performed microarray analysis of
PLAGL2-expressingneural stemcell-con-
taining cultures. Subsequent bioinfor-
matic analysis demonstrated strong
overexpression of members of the Wnt
pathway. This pathway, largely through
stabilization of b-catenin, is known to pro-
mote neural stem cell self-renewal and
inhibit differentiation (Shimizu et al.,
2008). To more closely link these findings,
Zheng et al. utilized neural stem cell and
GBM stem cell-like containing cultures to
demonstrate that the effects of PLAGL2
could be at least partially reversed by
inhibition of the Wnt pathway.
Much remains to be learned about
PLAGL2 amplification in GBM. Is such
amplification a primary tumor-causing
lesion in GBM? Is it found in specific
subsets of GBM? To what extent does
PLAGL2 cooperate with other genetic
and epigenetic alterations to promote
tumorigenesis? Does PLAGL2 activate
other oncogenic pathways besides the
Wnt pathway? Can PLAGL2 be targeted?
Despite these and many other remaining
questions, the studies outlined in Zheng
et al. provide strong support for a devel-
oping paradigm in tumor biology.418 Cancer Cell 17, May 18, 2010 ª2010 ElsAlthough many oncogenic mutations are
known to promote cell-cycle progression,
there is a growing recognition of the
importance of the inhibition of differentia-
tion and/or maintenance of self-renewal.
For example, BMPs can promote the
differentiation of GBM stem cell-like cells
under some circumstances, as they do
with adult neural stem cells (Piccirillo
et al., 2006). However, aberrant persistent
expression of specific BMP receptor iso-
forms inhibits this process, maintaining
self-renewal (Lee et al., 2008). Addition-
ally, deletion of Pten (Groszer et al., 2006)
or P53 (Meletis et al., 2006), common
mutations in GBM and many other
cancers, allow neural stem cells to remain
in a self-renewing state, in addition to their
many other effects. This maintenance of
self-renewal may allow for the accumula-
tion of other oncogenic mutations, tipping
cells into a cancerous state. Further stud-
ies will be needed to determine the entire
suite of changes that make at least a
subset ofGBMcells behave like stemcells
that are locked into a persistently self-
renewing state. Such a daunting task is
made more palatable by the rapid and
ever-growing interchange ofmethods and
concepts between stem cell and cancer
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